|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Ste. 400,South San Francisco,CA,US
|
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Sunesis Pharmaceuticals, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
83.33%
|
The widely used Sunesis Pharmaceuticals, Inc. email format is {f}{last} (e.g. [email protected]) with 83.33% adoption across the company.
To contact Sunesis Pharmaceuticals, Inc. customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.